Other analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a buy rating on shares of Bayer in a research note on Friday, October 20th. Citigroup reiterated a buy rating on shares of Bayer in a research note on Thursday, January 11th. BNP Paribas set a €130.00 ($154.76) price target on Bayer and gave the stock a buy rating in a research note on Monday, September 25th. Warburg Research set a €121.00 ($144.05) price target on Bayer and gave the stock a buy rating in a research note on Wednesday, September 20th. Finally, Jefferies Group set a €132.00 ($157.14) price target on Bayer and gave the stock a buy rating in a research note on Monday, September 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of €122.33 ($145.63).
Shares of Bayer (FRA BAYN) opened at €104.50 ($124.40) on Friday. The stock has a market capitalization of $86,300.00 and a PE ratio of 28.02. Bayer has a 52 week low of €99.69 ($118.68) and a 52 week high of €123.82 ($147.40).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.